Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash from Operations (2021 - 2025)

Prime Medicine's Cash from Operations history spans 5 years, with the latest figure at 37256000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 329.34% year-over-year to 37256000.0; the TTM value through Dec 2025 reached 162564000.0, down 32.31%, while the annual FY2025 figure was 162564000.0, 32.31% down from the prior year.
  • Cash from Operations reached 37256000.0 in Q4 2025 per PRME's latest filing, down from 35039000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 16245000.0 in Q4 2024 to a low of 67707000.0 in Q1 2024.
  • Average Cash from Operations over 5 years is 35050294.12, with a median of 39166000.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: soared 137.03% in 2024, then tumbled 329.34% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 13187000.0 in 2021, then crashed by 132.9% to 30713000.0 in 2022, then crashed by 42.82% to 43864000.0 in 2023, then skyrocketed by 137.03% to 16245000.0 in 2024, then plummeted by 329.34% to 37256000.0 in 2025.
  • Per Business Quant, the three most recent readings for PRME's Cash from Operations are 37256000.0 (Q4 2025), 35039000.0 (Q3 2025), and 41412000.0 (Q2 2025).